ipatasertib Report issue

Small molecule Experimental
AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW
  • Now
Ipatasertib (RG7440) is an experimental cancer drug in development by Roche. It is a small molecule inhibitor of AKT, which is a key component of the PI3K/AKT pathway. It was discovered by Array Biopharma and is currently in phase II trials for treatment of breast cancer.   Wikipedia

Chemistry

  • SMILES: CC(C)NC[C@@H](C(=O)N1CCN(CC1)c2ncnc3[C@H](O)C[C@@H](C)c23)c4ccc(Cl)cc4
  • InChIKey: GRZXWCHAXNAUHY-NSISKUIASA-N
  • Mol. Mass: 458.01
  • ALogP: 3.1
  • ChEMBL Molecule:
    ipatasertib  
More Chemistry

Pharmacology

Alternative names

2-(4-chlorophenyl)-1-(4-(7-hydroxy-5-methyl-6,7-dihydro-5h-cyclopenta(d)pyrimidin-4-yl)piperazin-1-yl)-3-(isopropylamino)propan-1-one | gdc-0068 | ipatasertib | rg-7440

Organizations (35)

Research & Development (35)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (16)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (16)


 

Breast Neoplasms (Phase 3)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Circulating Tumor DNA (Phase 2)

Endometrial Neoplasms (Phase 1/Phase 2)

Gastrointestinal Neoplasms (Phase 2)

Glioblastoma (Phase 1/Phase 2)

Healthy Volunteers (Phase 1)

Hepatic Insufficiency (Phase 1)

Neoplasm Metastasis (Phase 2)

Neoplasm, Residual (Phase 2)

Neoplasms (Phase 2)

Ovarian Neoplasms (Phase 2)

Prostatic Neoplasms (Phase 2)

Prostatic Neoplasms, Castration-Resistant (Phase 2)

Stomach Neoplasms (Phase 2)

Triple Negative Breast Neoplasms (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 45
  • # of Trial Organizations: 35

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue